A Randomized, Controlled Trial of Gabapentin Enacarbil in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Gabapentin enacarbil (GE n), a transported prodrug of gabapentin, provides sustained, dose‐proportional gabapentin exposure. The purpose of this study was to investigate the dose response of GE n to select the optimal dose(s) for clinical use in subsequent diabetic peripheral neuropathy (DPN) trials. Methods: This was a multicenter, randomized, double‐blind, double‐dummy, parallel group, placebo‐controlled trial with a study duration of approximately 20 weeks (Clinicaltrials.gov database, Identifier ! NCT 00643760). Pregabalin (PGB) (Lyrica®; Pfizer Inc.) was used as an active control to provide assay sensitivity of the trial. A total of 421 adult subjects with DPN were randomized in a ratio of 2:1:1:1:2 to receive oral GE n 3,600 mg/day, GE n 2,400 mg/day, GE n 1,200 mg/day, PGB 300 mg/day, or matching placebo, respectively. The primary efficacy endpoint was change from baseline to end of maintenance treatment with respect to the mean 24‐hour average pain intensity score based on an 11‐point Pain Intensity Numerical Rating Scale (PI‐NRS). Safety and tolerability assessments included treatment‐emergent adverse events (TEAE s), laboratory evaluations, vital signs, electrocardiograms (ECG), neurological examination, and pedal edema. Results: The adjusted mean difference vs. placebo at the end of maintenance treatment with respect to the mean 24‐hour average PI‐NRS pain intensity score for GE n 1,200 mg (−0.35; [95% CI: −1.02, 0.31]; P = 0.295), GE n 2,400 mg (−0.02; [95% CI: −0.71, 0.66]; P = 0.946), and GE n 3,600 mg (−0.55; [95% CI: −1.10, 0.01]; P = 0.105) was not statistically significant. The active control, PGB (300 mg/day), did not differentiate from placebo. Conclusion: Overall, none of the GE n treatment groups differentiated from placebo. Analyses of the secondary endpoints showed comparable results across treatment groups. However, the majority of the endpoints, including all of the pain endpoints, showed the largest numerical treatment difference was between GE n 3,600 mg and placebo. The active control, PGB (300 mg/day), did not differentiate from placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Young, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502
Tesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695 · cited 1×
“Any event 79 (66) 45 (73) 38 (68) 86 (74) 47 (71) Dizziness 7 (6) 9 (15) 8 (14) 16 (14) 9 (14) Somnolence 5 (4) 2 (3) 7 (13) 14 (12) 9 (14) Nausea 9 (8) 7 (11) 4 (7) 7 (6) 3 (5) Peripheral edema 5 (4) 2 (3) 0 11 (9) 11 (17) Headache 9 (8) 3 (5) 4 (7) 4 (3) 6 (9) Muscle spasms 4 (3) 6 (10) 0 11 (9) 3 (5) Diarrhea 6 (5)…”
Cited by
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & McQuay, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub2 · Cited by 690
Gabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561
Pregabalin for neuropathic pain in adults
Derry, S., Bell, R. F., Straube, S., Wiffen, P. J., Aldington, D., & Moore, R. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub3 · Cited by 364
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & Rice, A. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub3 · Cited by 292
Onakpoya, I. J., Thomas, E. T., Lee, J. J., Goldacre, B., & Heneghan, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023600 · Cited by 132
Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., & Namaka, M. (2015) · Pain Medicine · doi:10.1111/pme.12569 · Cited by 124
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“A large RCT (N = 421) of a gabapentin pro-drug, gabapentin enacarbil, however did not lead to significant reductions in the mean 24-h pain intensity score compared with placebo [53].”
BackgroundHuffman, C., Stacey, B. R., Tuchman, M., Burbridge, C., Li, C., Parsons, B., Pauer, L., Scavone, J. M., Behar, R., & Yurkewicz, L. (2015) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000198 · Cited by 37
Metadata
- Authors
- Rauck, R., Makumi, C. W., Schwartz, S., Graff, O., Meno‐Tetang, G., Bell, C. F., Kavanagh, S. T., & McClung, C. L.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2012-11-27
- Volume
- 13
- Issue
- 6
- Pages
- 485-496
- ISSN
- 1530-7085 (ISSN-L)
- 1533-2500
- OpenAlex
- W2085427610
- Cited by
- 61
- References
- 2
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.